Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy

International Journal of Urology

Volumn 11, Issue 7, 2004, Pages 494-500

  Uemura, Hiroji ^a   Nakamura, Masafumi ^a   Hasumi, Hisashi ^a   Sugiura, Shinpei ^a   Fujinami, Kiyoshi ^a   Miyoshi, Yasuhide ^a   Yao, Masahiro ^a   Kubota, Yoshinobu ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Percent free PSA; Prostate cancer; Repeat biopsy; ROC curve

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 4043175574     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00843.x     Document Type: Article

References (30)

1. Landis SH, Murray T, Bolden S et al. Cancer statistics, 1999. CA Cancer J. Clin. 1999; 49: 8-31.
2. San Francisco IF, Olumi AF, Kao J et al. Clinical management of prostatic intraepithelial neoplasia as diagnosed by extended needle biopsies. BJU Int. 2003; 91: 350-4.
3. Luderer AA, Chen YT, Soriano TF et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995; 46: 187-94.
4. Selley S, Donovan J, Faulkner A et al. Diagnosis, management and screening of early localised prostate cancer. Health Technol. Assess. 1997; 1: 1-96.
5. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-4.
6. Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20.
7. Morote J, Raventos CX, Lorente JA et al. Intraindividual variations of total and percent free serum prostatic-specific antigen levels in patients with normal digital rectal examination. Eur. Urol. 1999; 36: 111-15.
8. Catalona WJ, Southwick PC, Slawin KM et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 255-60.
9. Mian BM, Naya Y, Okihara K et al. Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology 2002; 60: 836-40.
10. Morote J, Raventos CX, Lorente JA et al. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng/mL. J. Urol. 1997; 158: 502-4.
11. Vashi AR, Wojno KJ, Henricks W et al. Determination of the 'reflex range' and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997; 49: 19-27.
12. Bangma CH, Rietbergen JB, Kranse R et al. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J. Urol. 1997; 157: 2191-6.
13. Beduschi MC, Oesterling JE. Prostate-specific antigen density. Urol. Clin. North Am. 1997; 24: 323-32.
14. Chon CH, Lai FC, McNeal JE et al. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J. Urol. 2002; 167: 2457-60.
15. Arai Y, Yoshiki T, Yoshida O. C-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate 1997; 30: 195-201.
16. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-7.
17. Djavan B, Ravery V, Zlotta A et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J. Urol. 2001; 166: 1679-83.
18. Roehrborn CG, Pickens GJ, Sanders JS. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Urology 1996; 47: 347-52.
19. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J. Urol. 2002; 167: 2435-9.
20. Sokoll LJ, Mangold LA, Partin AW et al. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. Urology 2002; 60: 18-23.
21. Haese A, Dworschack RT, Partin AW. Percent free prostate specific antigen in the total prostate specific antigen 2-4 ng/mL range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4-10 ng/mL range. J. Urol. 2002; 168: 504-8.
22. Han M, Potter SR, Partin AW. The role of free prostate-specific antigen in prostate cancer detection. Curr. Urol. Rep. 2000; 1: 78-82.
23. Stewart CS, Leibovich BC, Weaver AL et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J. Urol. 2001; 166: 86-91.
24. Rosser CJ, Broberg J, Case D et al. Detection of high-grade prostatic intraepithelial neoplasia with the five-region biopsy technique. Urology 1999; 54: 853-6.
25. Djavan B, Mazal P, Zlotta A et al. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study. Prostate 2001; 47: 111-17.
26. Davidson D, Bostwick DG, Qian J et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J. Urol. 1995; 154: 1295-9.
27. Tarle M, Kraljic I. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential problem for dormant and manifest cancer? Anticancer Res. 1997; 17: 1531-4.
28. Ukimura O, Durrani O, Babaian RJ. Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology 1997; 50: 66-72.
29. Letran JL, Blase AB, Loberiza FR et al. Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma. J. Urol. 1998; 160: 426-9.
30. Fleshner NE, O'Sullivan M, Fair WR. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J. Urol. 1997; 158: 505-8.